Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma
Authors:
Open Access
- 1 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (33) , e11872
Abstract
The long-term survival benefit of treating unresectable hepatocellular carcinoma (HCC) patients with transarterial chemoembolization (TACE) rather than conservative treatment remains controversial. This retrospective case-control study evaluated the survival of patients with unresectable HCC treated with TACE, relative to that of patients who received best supportive care. From January 2002 to December 2010, 522 of 2386 consecutive patients with unresectable HCC were enrolled. Patients were treated with TACE (n = 347) or best supportive care (non-TACE; n = 175). A survival analysis compared the survival of the 2 groups, as well as only those at Barcelona Clinic Liver Cancer Classification (BCLC)-C and Child-Pugh-B (39 TACE, 61 non-TACE).The median follow-up was 5 months (0.15–106 months). The overall median survival of the TACE group (8.0 months) was significantly longer than that of the non-TACE (2.0 months; P ≤ .01). Of the patients at BCLC-C and Child-Pugh-B, the overall median survivals of the TACE and non-TACE patients were 6.0 and 2.0 months, respectively (P ≤ .01); and the 1, 2, 3, 5, and 8-year overall survival rates were significantly superior in the TACE group (P ≤ .01). For all the patients, the independent predictors of survival were treatment modalities, portal vein tumor thrombosis, alpha-fetoprotein, and BCLC stage. Regarding the TACE patients, contributors to prognosis were portal vein tumor thrombosis, alpha-fetoprotein level, and the number of TACE procedures. TACE for unresectable HCC was associated with longer survival compared with best supportive care, especially for patients at BCLC-C and Child-Pugh-B.Keywords
This publication has 30 references indexed in Scilit:
- HBV Induced HCC: Major Risk Factors from Genetic to Molecular LevelBioMed Research International, 2013
- Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysisBMC Gastroenterology, 2013
- Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitorsCritical Reviews in Oncology/Hematology, 2011
- Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative StudyAnnals of Surgical Oncology, 2010
- Non‐surgical treatment of hepatocellular carcinomaHPB, 2005
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Chemoembolization for primary liver cancerEuropean Journal of Surgical Oncology, 2002
- Hepatocellular carcinomaJournal of Hepatology, 1992
- Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patientsHepatology, 1990
- Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patientsCancer, 1989